Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia

Obstetrics and Gynecology

Volumn 116, Issue 1, 2010, Pages 114-120

  Costantine, Maged M ^a   Tamayo, Esther ^a   Lu, Fangxian ^a   Bytautiene, Egle ^a   Longo, Monica ^a   Hankins, Gary D V ^a   Saade, George R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENYLEPHRINE; PRAVASTATIN; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; SFLT 1 GENE; WEIGHT;

ACETYLCHOLINE; ANIMALS; FEMALE; MICE; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASOMOTOR SYSTEM;

EID: 77954040082     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181e10ebd     Document Type: Article

References (31)

1. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99: 159-167
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclamp-sia. N Engl J Med 2004;350:672-683
3. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
4. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-1594
5. Berends AL, de Groot CJ, Sijbrands EJ, Sie MP, Benneheij SH, Pal R, et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension 2008;51:1-8.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
7. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008;112(2 pt 1):359-372
8. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
9. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-1781
10. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson G, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of pre-eclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007;196:396.e1-7
11. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and protein-uria in preeclampsia. J Clin Invest 2003;111:649-658
12. Wei K, Kuhnert F, Kuo CJ. Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathway. J Mol Med 2008;86:161-169
13. Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduced cardiovascular risk factors in their offspring. Hypertension 2008;51:939-944
14. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
15. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39:397-412.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357
18. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4-12.
19. U.S. Food and Drug Administration. Drug bulletin. Fed Reg 1980;44:37434-37467
20. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906-908
21. Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008;26:175-177
22. Díaz-Zagoya JC, Asenjo-Barrón JC, Cárdenas- Vázquez R, Martínez F, Juárez-Oropeza MA. Comparative toxicity of high doses of vastatins currently used by clinicians in CD-1 male mice fed with a hypercholesterolemic diet. Life Sci 1999;65:947-956
23. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004;131:287-298
24. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885
25. Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schü rger S, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004;37:2064-2071
26. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004;110:1296-1302
27. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001;7:693-698
28. Kreiser D, Baum M, Seidman DS, Fanaroff A, Shah D, Hendler I, et al. End tidal carbon monoxide levels are lower in women with gestational hypertension and pre-eclampsia. J Perinatol 2004;24:213-217.
29. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007;115:1789-1797
30. Chen SD, Hu CJ, Yang DI, Nassief A, Chen H, Yin K, et al. Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci 2005;1042:357-364
31. Nishimoto-Hazuku A, Hirase T, Ide N, Ikeda Y, Node K. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothe-lial cells. J Cardiovasc Pharmacol 2008;51:267-273